Trials / Completed
CompletedNCT03419572
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 689 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.
Detailed description
The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data collection | Only available evaluations as decided by the investigator based on local clinical practice will be collected. |
Timeline
- Start date
- 2018-04-24
- Primary completion
- 2022-05-19
- Completion
- 2022-05-19
- First posted
- 2018-02-05
- Last updated
- 2022-08-15
Locations
91 sites across 11 countries: Austria, Belgium, Czechia, France, Germany, Greece, Italy, Netherlands, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03419572. Inclusion in this directory is not an endorsement.